uniQure N.V. (LON: 0EE0)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 605.13M |
| Revenue (ttm) | 21.33M |
| Net Income (ttm) | -178.69M |
| Shares Out | n/a |
| EPS (ttm) | -3.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,434 |
| Average Volume | 5,795 |
| Open | 15.28 |
| Previous Close | 14.87 |
| Day's Range | 14.77 - 15.28 |
| 52-Week Range | 4.94 - 22.20 |
| Beta | n/a |
| RSI | 53.12 |
| Earnings Date | Feb 28, 2025 |
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT... [Read more]
Financial Performance
In 2023, uniQure's revenue was $15.84 million, a decrease of -85.12% compared to the previous year's $106.48 million. Losses were -$308.48 million, 143.3% more than in 2022.
Financial numbers in USD Financial StatementsNews
uniQure prices equity offering
uniQure Announces Pricing of its Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
uniQure filed for automatic mixed securities shelf
uniQure Announces Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
Final Trade: DVN, QURE, GOOGL, DFH
The final trades of the day with the Fast Money traders.
uniQure's AMT-130: A Bold Step For Huntington's, But Not Without Hurdles
uniQure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges despite strong clinical data.
Raymond James, Cantor bullish on uniQure following FDA update
Raymond James and Cantor both released bullish notes on uniQure (QURE) Tuesday following an update on the company's Huntington's disease therapy AMT-130. Read more here.
uniQure stock rockets 90% on FDA update for AMT-130
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on Tuesday. Shares of United Natural Foods, Inc . (NYSE: UNFI) rose sharply during Tuesday's session following better-than-...
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
UniQure stock nearly doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease treatment.
Why Is uniQure Stock Skyrocketing On Tuesday?
uniQure stock surges after FDA agrees ... Full story available on Benzinga.com
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease
~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Applica...
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington's disease ~
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs...
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity
uniQure N.V. released positive 24-month trial data for AMT-130 gene therapy for Huntington's Disease, leading to a significant stock price increase. The company has aggressively restructured to extend...
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegener...
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~
What Led To A 150% Rise In UniQure Stock In A Week?
uniQure stock (NASDAQ: QURE), a gene therapy company, has seen a stellar 150% rise in a week, faring significantly better than its peer – Editas Medicine stock –, up 12%. This massive rise in QURE sto...
uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts
uniQure reported positive interim results across phase 1/2 studies, using AMT-130 for the treatment of patients with Huntington's Disease, leading to an 80% slowing of disease progression. The company...
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease
~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the compo...
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
~ Proposed divestiture streamlines uniQure's focus and represents an important milestone in its ongoing effort to significantly reduce operating expenses ~
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
Strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. BOSTON and INDIANAPOLIS , July 1, 2024...